Tripos, CeNeS extend agreement to develop Parkinson's treatment

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Tripos, Inc. extended its agreement with CeNeS Pharmaceuticals plc to develop catechol-O-methyltransferase (COMT) inhibitors to treat Parkinson's disease.

Terms of the agreement were not disclosed.

Since 2003, the two companies have identified several series of novel active compounds, achieving a chemical breakaway from currently marketed COMT inhibitors.

CeNeS is a U.K.-based central nervous system-focused biopharmaceutical company.

Tripos, based in St. Louis, provides chemistry research products to the biotech, pharmaceutical and life sciences sectors.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.